Abstract
Poly(ethylene glycol) (PEG)ylation of peptides and proteins creates significant challenges for detailed structural characterization, such as PEG heterogeneity, site of addition and number of attached PEGylated moieties. Recently, we published a novel LC/MS methodology with a post-column addition of amines to obtain accurate masses of PEGylated peptides and proteins. The accurate masses can be used to assign the structures and number of attached PEGs [15], but the PEGylation site remains unclear in situations where multiple potential attachments are involved. Here, we present a methodology combining in-source fragmentation (ISF) with CID-MS/MS to elucidate the PEGylated sites in PEGylated products. All PEGylated samples, either prepared in acidic solution, or collected from a RP-HPLC stream, were first ionized via ISF to produce products containing small PEG fragment attachment, and then those fragment ions obtained were sequenced via CID MS/MS to deduce the PEGylation site. The methodology was successfully applied to PEGylated glucagon and IgG4 antibody light chain, which demonstrated that the small PEG fragments attached were stable during the CID activation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Walsh, G. Biopharmaceutical Benchmarks. Nat. Biotechnol 2000, 18, 831–833.
Bruckdorfer, T.; Marder, O.; Albericio, F. From Production of Peptides in Milligram Amounts for Research to Multi-Ton Quantities for Drugs of the Future. Curr. Pharm. Biotechnol 2004, 5, 29–43.
Sinclair, A. M.; Elliott, S. Glycoengineering: The Effect of Glycosylation on the Properties of Therapeutic Proteins. J. Pharm. Sci 2005, 94, 1626–1635.
Wong, K.; Cleland, L. G.; Poznansky, M. J. Enhanced Anti-Inflammatory Effect and Reduced Immunogenicity of Bovine Liver Superoxide Dismutase by Conjugation with Homologous Albumin. Agents Actions 1980, 10, 231–239.
Syed, S.; Schuyler, P. D.; Kulczycky, M.; Sheffield, W. P. Potent Antithrombin Activity and Delayed Clearance from the Circulation Characterize Recombinant Hirudin Genetically Fused to Albumin. Blood 1997, 89, 3243–3252.
Lyczak, J. B.; Morrison, S. L. Biological and Pharmacokinetic Properties of a Novel Immunoglobulin-CD4 Fusion Protein. Arch. Virol 1994, 139, 189–196.
Abuchowski, A.; McCoy, J. R.; Palczuk, N. C.; van Es, T.; Davis, F. F. Effect of Covalent Attachment of Polyethylene Glycol on Immunogenicity and Circulating Life of Bovine Liver Catalase. J. Biol. Chem 1977, 252, 3582–3586.
Davis, F. F. The Origin of PEGnology. Adv. Drug Deliv. Rev 2002, 54, 457–458.
Harris, J. M.; Chess, R. B. Effect of PEGylation on Pharmaceuticals. Nat. Rev. Drug Discov 2003, 2, 214–221.
Veronese, F. M.; Harris, J. M. Introduction and Overview of Peptide and Protein PEGylation. Adv. Drug Deliv. Rev 2002, 54, 453–456.
Veronese, F. M.; Mero, A. The Impact of PEGylation on Biological Therapies. BioDrugs 2008, 22, 315–329.
Lee, K. C.; Moon, S. C.; Park, M. O.; Lee, J. T.; Na, D. H.; Yoo, S. D.; Lee, H. S.; DeLuca, P. P. Isolation, Characterization, and Stability of Positional Isomers of Mono-PEGylated Salmon Calcitonins. Pharm. Res 1999, 16, 813–818.
Na, D. H.; Youn, Y. S.; Lee, K. C. Optimization of the PEGylation Process of a Peptide by Monitoring with Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. Rapid Commun. Mass Spectrom 2003, 17, 2241–2244.
Foser, S.; Schacher, A.; Weyer, K. A.; Brugger, D.; Dietel, E.; Marti, S.; Schreitmuller, T. Isolation, Structural Characterization, and Antiviral Activity of Positional Isomers of Mono-PEGylated Interferon α-2a (PEGASYS). Protein Expr. Purif 2003, 30, 78–87.
Huang, L.; Gough, P. C.; Defelippis, M. R. Characterization of Poly(ethylene glycol) and PEGylated Products by LC/MS with Post-Column Addition of Amines. Anal. Chem 2009, 81, 567–577.
Iafelice, R.; Cristoni, S.; Caccia, D.; Russo, R.; Rossi-Bernardi, L.; Lowe, K. C.; Perrella, M. Identification of the Sites of Deoxyhemoglobin PEGylation. Biochem. J 2007, 403, 189–196.
Roberts, M. J.; Harris, J. M. Attachment of Degradable Poly(ethylene glycol) to Proteins Has the Potential to Increase Therapeutic Efficacy. J. Pharm. Sci 1998, 87, 1440–1445.
Yoo, C.; Suckau, D.; Sauerland, V.; Ronk, M.; Ma, M. Toward Top-Down Determination of PEGylation Site Using MALDI In-Source Decay MS Analysis. J. Am. Soc. Mass Spectrom 2009, 20, 326–333.
Veronese, F. M. Peptide and Protein PEGylation: A Review of Problems and Solutions. Biomaterials 2001, 22, 405–417.
Clark, R.; Olson, K.; Fuh, G.; Marian, M.; Mortensen, D.; Teshima, G.; Chang, S.; Chu, H.; Mukku, V.; Canova-Davis, E.; Somers, T.; Cronin, M.; Winkler, M.; Wells, J. A. Long-Acting Growth Hormones Produced by Conjugation with Polyethylene Glycol. J. Biol. Chem 1996, 271, 21969–21977.
Veronese, F. M.; Sacca, B.; de Laureto, P.; Sergi, M.; Caliceti, P.; Schiavon, O.; Orsolini, P. New PEGs for Peptide and Protein Modification, Suitable for Identification of the PEGylation Site. Bioconj. Chem 2001, 12, 62–70.
Vestling, M. M.; Murphy, C. M.; Keller, D. A.; Fenselau, C.; Dedinas, J.; Ladd, D. L.; Olsen, M. A. A Strategy for Characterization of Polyethylene Glycol-Derivatized Proteins: A Mass Spectrometric Analysis of the Attachment Sites in Polyethylene Glycol-Derivatized Superoxide Dismutase. Drug Metab. Dispos 1993, 21, 911–917.
Lee, H.; Park, T. G. A Novel Method for Identifying PEGylation Sites of Protein Using Biotinylated PEG Derivatives. J. Pharm. Sci 2003, 92, 97–103.
Wang, Y. S.; Youngster, S.; Bausch, J.; Zhang, R.; McNemar, C.; Wyss, D. F. Identification of the Major Positional Isomer of PEGylated Interferon α-2b. Biochemistry 2000, 39, 10634–10640.
Salmaso, S.; Bersani, S.; Scomparin, A.; Mastrotto, F.; Scherpfer, R.; Tonon, G.; Caliceti, P. Tailored PEG for rh-G-CSF Analogue Site-Specific Conjugation. Bioconjug. Chem 2009, 20, 1179–1185.
Roberts, M. J.; Bentley, M. D.; Harris, J. M. Chemistry for Peptide and Protein PEGylation. Adv. Drug Delivery Rev 2002, 54, 459–476.
Carr, A.; Second, T.; Cummins, R.; Viner, R.; Huang, L. Characterization of PEGylated Peptides and Site Localization of Attachment with High Resolution ETD Mass Spectrometry. Proceedings of the 57th ASMS Conference on Mass Spectrometry and Allied Topics; Philadelphia, PA, May, 2009.
Jorgensen, K. E.; Moller, J. V. Use of Flexible Polymers as Probes of Glomerular Pore Size. Am. J. Physiol 1979, 236, F103-F111.
Kang, J. S.; Deluca, P. P.; Lee, K. C. Emerging PEGylated Drugs. Expert Opin. Emerg. Drugs 2009, 14, 363–380.
Huang, L.; Mitchell, C. E. High-Throughput LC/MS Methodology for α(1→3)Gal Determination of Recombinant Monoclonal Antibodies. In Therapeutic Protein, Methods, and Protocols, Smales, C. M.; James, D. C., Eds.; Humana Press: Totowa, NJ, 2005; p. 411–419.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published online January 25, 2010
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Lu, X., Gough, P.C., DeFelippis, M.R. et al. Elucidation of PEGylation site with a combined approach of in-source fragmentation and CID MS/MS. J Am Soc Mass Spectrom 21, 810–818 (2010). https://doi.org/10.1016/j.jasms.2010.01.011
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.jasms.2010.01.011